RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

Benzinga Newsdesk www.benzinga.com Positive 89.8%

Neg 0% Neu 0% Pos 89.8%

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.